

William Vainchenker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9433798/publications.pdf>

Version: 2024-02-01

157
papers

18,520
citations

13827

67
h-index

12233

133
g-index

164
all docs

164
docs citations

164
times ranked

15384
citing authors

#	ARTICLE	IF	CITATIONS
1	Germline ATG2B/GSKIP-containing 14q32 duplication predisposes to early clonal hematopoiesis leading to myeloid neoplasms. <i>Leukemia</i> , 2022, 36, 126-137.	3.3	10
2	Macrophage migration inhibitory factor is overproduced through EGR1 in TET2 ^{low} resting monocytes. <i>Communications Biology</i> , 2022, 5, 110.	2.0	8
3	An inherited gain-of-function risk allele in <i>EPOR</i> predisposes to familial <i>JAK2</i> ^{V617F} myeloproliferative neoplasms. <i>British Journal of Haematology</i> , 2022, 198, 131-136.	1.2	6
4	CCND2 mutations are infrequent events in BCR-ABL1 negative myeloproliferative neoplasm patients. <i>Haematologica</i> , 2021, 106, 863-864.	1.7	5
5	IFN: Jekyll and Hyde. <i>Blood</i> , 2021, 137, 291-293.	0.6	0
6	<i>ATG2B/GSKIP</i> in <i>de novo</i> acute myeloid leukemia (AML): high prevalence of germline predisposition in French West Indies. <i>Leukemia and Lymphoma</i> , 2021, 62, 1770-1773.	0.6	5
7	Role of Rho-GTPases in megakaryopoiesis. <i>Small GTPases</i> , 2021, 12, 399-415.	0.7	5
8	Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms. <i>Blood</i> , 2021, 138, 2142-2148.	0.6	23
9	CALR mutant protein rescues the response of MPL p.R464G variant associated with CAMT to eltrombopag. <i>Blood</i> , 2021, 138, 480-485.	0.6	3
10	Dual role of EZH2 in megakaryocyte differentiation. <i>Blood</i> , 2021, 138, 1603-1614.	0.6	5
11	Induced Pluripotent Stem Cells Enable Disease Modeling and Drug Screening in Calreticulin del52 and ins5 Myeloproliferative Neoplasms. <i>HemaSphere</i> , 2021, 5, e593.	1.2	5
12	PPAR δ agonists promote the resolution of myelofibrosis in preclinical models. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	4
13	Functional Consequences of Mutations in Myeloproliferative Neoplasms. <i>HemaSphere</i> , 2021, 5, e578.	1.2	22
14	Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFN γ in myeloproliferative neoplasms. <i>Blood</i> , 2021, 138, 2231-2243.	0.6	25
15	JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	22
16	The megakaryocyte: a cell with 3 faces as a mythic god?. <i>Blood</i> , 2021, 138, 1199-1200.	0.6	1
17	Lyl-1 regulates primitive macrophages and microglia development. <i>Communications Biology</i> , 2021, 4, 1382.	2.0	8
18	Multilayer intraclonal heterogeneity in chronic myelomonocytic leukemia. <i>Haematologica</i> , 2020, 105, 112-123.	1.7	13

#	ARTICLE	IF	CITATIONS
19	Megakaryocyte polyploidization: role in platelet production. <i>Platelets</i> , 2020, 31, 707-716.	1.1	20
20	Knock-in of murine Calr del52 induces essential thrombocythemia with slow-rising dominance in mice and reveals key role of Calr exon 9 in cardiac development. <i>Leukemia</i> , 2020, 34, 510-521.	3.3	36
21	Immunosuppression by Mutated Calreticulin Released from Malignant Cells. <i>Molecular Cell</i> , 2020, 77, 748-760.e9.	4.5	77
22	Calreticulin del52 and ins5 knock-in mice recapitulate different myeloproliferative phenotypes observed in patients with MPN. <i>Nature Communications</i> , 2020, 11, 4886.	5.8	27
23	Megakaryocytes tame erythropoiesis with TGF β 1. <i>Blood</i> , 2020, 136, 1016-1017.	0.6	5
24	Regulation of Platelet Production and Life Span: Role of Bcl-xL and Potential Implications for Human Platelet Diseases. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7591.	1.8	24
25	A p53-JAK-STAT connection involved in myeloproliferative neoplasm pathogenesis and progression to secondary acute myeloid leukemia. <i>Blood Reviews</i> , 2020, 42, 100712.	2.8	16
26	Germline genetic factors in the pathogenesis of myeloproliferative neoplasms. <i>Blood Reviews</i> , 2020, 42, 100710.	2.8	16
27	Different impact of calreticulin mutations on human hematopoiesis in myeloproliferative neoplasms. <i>Oncogene</i> , 2020, 39, 5323-5337.	2.6	12
28	TET2 haploinsufficiency alters reprogramming into induced pluripotent stem cells. <i>Stem Cell Research</i> , 2020, 44, 101755.	0.3	5
29	The Pediatric Acute Leukemia Fusion Oncogene ETO2 α GLIS2 Increases Self-Renewal and Alters Differentiation in a Human Induced Pluripotent Stem Cells-Derived Model. <i>HemaSphere</i> , 2020, 4, e319.	1.2	8
30	A new efficient tool for non-invasive diagnosis of fetomaternal platelet antigen incompatibility. <i>British Journal of Haematology</i> , 2020, 190, 787-798.	1.2	6
31	Remodeling of Bone Marrow Hematopoietic Stem Cell Niches Promotes Myeloid Cell Expansion during Premature or Physiological Aging. <i>Cell Stem Cell</i> , 2019, 25, 407-418.e6.	5.2	202
32	The role of the thrombopoietin receptor MPL in myeloproliferative neoplasms: recent findings and potential therapeutic applications. <i>Expert Review of Hematology</i> , 2019, 12, 437-448.	1.0	20
33	Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants. <i>Blood</i> , 2019, 133, 2669-2681.	0.6	74
34	Description of a knock-in mouse model of JAK2V617F MPN emerging from a minority of mutated hematopoietic stem cells. <i>Blood</i> , 2019, 134, 2383-2387.	0.6	18
35	Disrupted filamin A β 3 interaction induces macrothrombocytopenia by increasing RhoA activity. <i>Blood</i> , 2019, 133, 1778-1788.	0.6	27
36	Rare type 1-like and type 2-like calreticulin mutants induce similar myeloproliferative neoplasms as prevalent type 1 and 2 mutants in mice. <i>Oncogene</i> , 2019, 38, 1651-1660.	2.6	7

#	ARTICLE	IF	CITATIONS
37	New pathogenic mechanisms induced by germline erythropoietin receptor mutations in primary erythrocytosis. <i>Haematologica</i> , 2018, 103, 575-586.	1.7	17
38	Megakaryocyte and polyploidization. <i>Experimental Hematology</i> , 2018, 57, 1-13.	0.2	73
39	JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders. <i>F1000Research</i> , 2018, 7, 82.	0.8	126
40	Myelodysplastic Syndromes: Mechanisms, Diagnosis, and Treatment. , 2018, , 563-563.		0
41	Secreted Mutant Calreticulins As Rogue Cytokines Trigger Thrombopoietin Receptor Activation Specifically in CALR Mutated Cells: Perspectives for MPN Therapy. <i>Blood</i> , 2018, 132, 4-4.	0.6	32
42	P53 deletion and NrasG12D cooperate for AML. <i>Blood</i> , 2017, 129, 271-273.	0.6	0
43	Acquired TET 2 mutation in one patient with familial platelet disorder with predisposition to AML led to the development of preleukaemic clone resulting in T2 ALL and AML M0. <i>Journal of Cellular and Molecular Medicine</i> , 2017, 21, 1237-1242.	1.6	10
44	Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. <i>Blood</i> , 2017, 129, 667-679.	0.6	444
45	Critical role of the HDAC6 cortactin axis in human megakaryocyte maturation leading to a proplatelet-formation defect. <i>Nature Communications</i> , 2017, 8, 1786.	5.8	35
46	CXCL12/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent manner. <i>Oncotarget</i> , 2017, 8, 54082-54095.	0.8	25
47	Genetic Alterations of the Thrombopoietin/MPL/JAK2 Axis Impacting Megakaryopoiesis. <i>Frontiers in Endocrinology</i> , 2017, 8, 234.	1.5	39
48	Identification of MPL R102P Mutation in Hereditary Thrombocytosis. <i>Frontiers in Endocrinology</i> , 2017, 8, 235.	1.5	22
49	Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis. <i>Journal of Clinical Investigation</i> , 2017, 127, 1316-1320.	3.9	65
50	Recent advances in understanding myelofibrosis and essential thrombocythemia. <i>F1000Research</i> , 2016, 5, 700.	0.8	39
51	Uncoupling of the Hippo and Rho pathways allows megakaryocytes to escape the tetraploid checkpoint. <i>Haematologica</i> , 2016, 101, 1469-1478.	1.7	18
52	An incomplete trafficking defect to the cell-surface leads to paradoxical thrombocytosis for human and murine MPL P106L. <i>Blood</i> , 2016, 128, 3146-3158.	0.6	16
53	Activity of nonmuscle myosin II isoforms determines localization at the cleavage furrow of megakaryocytes. <i>Blood</i> , 2016, 128, 3137-3145.	0.6	17
54	Eltrombopag, a potent stimulator of megakaryopoiesis. <i>Haematologica</i> , 2016, 101, 1443-1445.	1.7	14

#	ARTICLE	IF	CITATIONS
55	Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. <i>Blood</i> , 2016, 127, 333-342.	0.6	149
56	EZH2: a molecular switch of the MPN phenotype. <i>Blood</i> , 2016, 127, 3297-3298.	0.6	2
57	Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. <i>Blood</i> , 2016, 127, 1317-1324.	0.6	220
58	Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. <i>Blood</i> , 2016, 127, 1325-1335.	0.6	261
59	Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. <i>Nature Communications</i> , 2016, 7, 10767.	5.8	177
60	TET2-mediated 5-hydroxymethylcytosine induces genetic instability and mutagenesis. <i>DNA Repair</i> , 2016, 43, 78-88.	1.3	21
61	<i>ATG2B</i> and <i>GSKIP</i> : 2 new genes predisposing to myeloid malignancies. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1094564.	0.3	10
62	P53 activation inhibits all types of hematopoietic progenitors and all stages of megakaryopoiesis. <i>Oncotarget</i> , 2016, 7, 31980-31992.	0.8	38
63	Concise Review: Induced Pluripotent Stem Cells as New Model Systems in Oncology. <i>Stem Cells</i> , 2015, 33, 2887-2892.	1.4	8
64	Level of RUNX1 activity is critical for leukemic predisposition but not for thrombocytopenia. <i>Blood</i> , 2015, 125, 930-940.	0.6	87
65	TET2 loss, a rescue of JAK2V617F HSCs. <i>Blood</i> , 2015, 125, 212-213.	0.6	1
66	A <i>CALR</i> Mutation Preceding <i>BCR-ABL1</i> in an Atypical Myeloproliferative Neoplasm. <i>New England Journal of Medicine</i> , 2015, 372, 688-690.	13.9	41
67	Germline duplication of <i>ATG2B</i> and <i>GSKIP</i> predisposes to familial myeloid malignancies. <i>Nature Genetics</i> , 2015, 47, 1131-1140.	9.4	107
68	Emergence of a <i>BCR-ABL1</i> Translocation in a Patient With the <i>JAK2</i> V617F Mutation: Evidence for Secondary Acquisition of <i>BCR-ABL1</i> in the <i>JAK2</i> V617F Clone. <i>Journal of Clinical Oncology</i> , 2014, 32, e76-e79.	0.8	22
69	p19INK4d Controls Hematopoietic Stem Cells in a Cell-Autonomous Manner during Genotoxic Stress and through the Microenvironment during Aging. <i>Stem Cell Reports</i> , 2014, 3, 1085-1102.	2.3	27
70	Genetic Basis of Congenital Erythrocytosis: Mutation Update and Online Databases. <i>Human Mutation</i> , 2014, 35, 15-26.	1.1	101
71	Myeloproliferative Neoplasms: JAK2 Signaling Pathway as a Central Target for Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, S23-S35.	0.2	23
72	Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors. <i>Blood</i> , 2014, 123, 1372-1383.	0.6	69

#	ARTICLE	IF	CITATIONS
73	Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients. <i>Cancer Discovery</i> , 2014, 4, 1088-1101.	7.7	213
74	TET2 Deficiency Inhibits Mesoderm and Hematopoietic Differentiation in Human Embryonic Stem Cells. <i>Stem Cells</i> , 2014, 32, 2084-2097.	1.4	34
75	The formin DIAPH1 (mDia1) regulates megakaryocyte proplatelet formation by remodeling the actin and microtubule cytoskeletons. <i>Blood</i> , 2014, 124, 3967-3977.	0.6	59
76	Defective endomitosis during megakaryopoiesis leads to thrombocytopenia in Fanca ^{-/-} mice. <i>Blood</i> , 2014, 124, 3613-3623.	0.6	23
77	A new form of macrothrombocytopenia induced by a germ-line mutation in the PRKACG gene. <i>Blood</i> , 2014, 124, 2554-2563.	0.6	69
78	JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation. <i>Blood</i> , 2014, 124, 2104-2115.	0.6	45
79	Thrombocytopenia-associated mutations in the ANKRD26 regulatory region induce MAPK hyperactivation. <i>Journal of Clinical Investigation</i> , 2014, 124, 580-591.	3.9	163
80	Calr Mutants Retroviral Mouse Models Lead to a Myeloproliferative Neoplasm Mimicking an Essential Thrombocythemia Progressing to a Myelofibrosis. <i>Blood</i> , 2014, 124, 157-157.	0.6	11
81	Clonal architecture of chronic myelomonocytic leukemias. <i>Blood</i> , 2013, 121, 2186-2198.	0.6	232
82	Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2013, 31, 2428-2436.	0.8	462
83	Combination treatment for myeloproliferative neoplasms using JAK and pan- <i>class I PI3K</i> inhibitors. <i>Journal of Cellular and Molecular Medicine</i> , 2013, 17, 1397-1409.	1.6	50
84	Concomitant germline <i>RUNX1</i> and acquired <i>ASXL1</i> mutations in a T-cell acute lymphoblastic leukemia. <i>European Journal of Haematology</i> , 2013, 91, 277-279.	1.1	25
85	JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFN γ . <i>Blood</i> , 2013, 122, 1464-1477.	0.6	122
86	Heterozygous and Homozygous JAK2V617F States Modeled by Induced Pluripotent Stem Cells from Myeloproliferative Neoplasm Patients. <i>PLoS ONE</i> , 2013, 8, e74257.	1.1	32
87	RUNX1-induced silencing of non-muscle myosin heavy chain IIB contributes to megakaryocyte polyploidization. <i>Nature Communications</i> , 2012, 3, 717.	5.8	122
88	Presence of a defect in karyokinesis during megakaryocyte endomitosis. <i>Cell Cycle</i> , 2012, 11, 4385-4389.	1.3	21
89	Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes. <i>Blood</i> , 2012, 119, 4625-4635.	0.6	49
90	Dysmegakaryopoiesis of FPD/AML pedigrees with constitutional RUNX1 mutations is linked to myosin II deregulated expression. <i>Blood</i> , 2012, 120, 2708-2718.	0.6	93

#	ARTICLE	IF	CITATIONS
91	MYH10 protein expression in platelets as a biomarker of RUNX1 and FLI1 alterations. <i>Blood</i> , 2012, 120, 2719-2722.	0.6	68
92	TET2, a tumor suppressor in hematological disorders. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2012, 1825, 173-177.	3.3	16
93	Down-regulation of the RUNX1-target gene NR4A3 contributes to hematopoiesis deregulation in familial platelet disorder/acute myelogenous leukemia. <i>Blood</i> , 2011, 118, 6310-6320.	0.6	53
94	Monocytic cells derived from human embryonic stem cells and fetal liver share common differentiation pathways and homeostatic functions. <i>Blood</i> , 2011, 117, 3065-3075.	0.6	45
95	Thrombocytopenia resulting from mutations in filamin A can be expressed as an isolated syndrome. <i>Blood</i> , 2011, 118, 5928-5937.	0.6	148
96	TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event during Human Lymphomagenesis. <i>Cancer Cell</i> , 2011, 20, 25-38.	7.7	792
97	Myeloproliferative Neoplasms: Molecular Pathophysiology, Essential Clinical Understanding, and Treatment Strategies. <i>Journal of Clinical Oncology</i> , 2011, 29, 573-582.	0.8	272
98	New mutations and pathogenesis of myeloproliferative neoplasms. <i>Blood</i> , 2011, 118, 1723-1735.	0.6	346
99	FLT3-Mediated p38 β -MAPK Activation Participates in the Control of Megakaryopoiesis in Primary Myelofibrosis. <i>Cancer Research</i> , 2011, 71, 2901-2915.	0.4	46
100	Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors. <i>Blood</i> , 2011, 118, 2551-2555.	0.6	163
101	Orientation-specific signalling by thrombopoietin receptor dimers. <i>EMBO Journal</i> , 2011, 30, 4398-4413.	3.5	83
102	A major role of TGF β 1 in the homing capacities of murine hematopoietic stem cell/progenitors. <i>Blood</i> , 2010, 116, 1244-1253.	0.6	34
103	Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. <i>Blood</i> , 2010, 116, 783-787.	0.6	148
104	Aurora B is dispensable for megakaryocyte polyploidization, but contributes to the endomitotic process. <i>Blood</i> , 2010, 116, 2345-2355.	0.6	37
105	Two routes to leukemic transformation after a JAK2 mutation in a positive myeloproliferative neoplasm. <i>Blood</i> , 2010, 115, 2891-2900.	0.6	269
106	Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. <i>Blood</i> , 2010, 116, 1132-1135.	0.6	121
107	A Senescence-Like Cell-Cycle Arrest Occurs During Megakaryocytic Maturation: Implications for Physiological and Pathological Megakaryocytic Proliferation. <i>PLoS Biology</i> , 2010, 8, e1000476.	2.6	81
108	Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor. <i>Blood</i> , 2010, 115, 1037-1048.	0.6	68

#	ARTICLE	IF	CITATIONS
109	TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. <i>Haematologica</i> , 2009, 94, 1676-1681.	1.7	234
110	An activating mutation in the <i>CSF3R</i> gene induces a hereditary chronic neutrophilia. <i>Journal of Experimental Medicine</i> , 2009, 206, 1701-1707.	4.2	75
111	Mutation in <i>TET2</i> in Myeloid Cancers. <i>New England Journal of Medicine</i> , 2009, 360, 2289-2301.	13.9	1,614
112	Analysis of the Ten-Eleven Translocation 2 (TET2) gene in familial myeloproliferative neoplasms. <i>Blood</i> , 2009, 114, 1628-1632.	0.6	96
113	Molecular and Genetic Bases of Myeloproliferative Disorders: Questions and Perspectives. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, S329-S339.	1.4	13
114	Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines. <i>Blood</i> , 2009, 114, 1842-1851.	0.6	24
115	A common bipotent progenitor generates the erythroid and megakaryocyte lineages in embryonic stem cell-derived primitive hematopoiesis. <i>Blood</i> , 2009, 114, 1506-1517.	0.6	142
116	MAL/SRF complex is involved in platelet formation and megakaryocyte migration by regulating MYL9 (MLC2) and MMP9. <i>Blood</i> , 2009, 114, 4221-4232.	0.6	77
117	TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). <i>Blood</i> , 2009, 114, 3285-3291.	0.6	264
118	The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model. <i>Journal of Clinical Investigation</i> , 2009, 119, 852-64.	3.9	80
119	JAKs in pathology: Role of Janus kinases in hematopoietic malignancies and immunodeficiencies. <i>Seminars in Cell and Developmental Biology</i> , 2008, 19, 385-393.	2.3	153
120	A nonsynonymous SNP in the <i>ITGB3</i> gene disrupts the conserved membrane-proximal cytoplasmic salt bridge in the $\beta 3$ integrin and cosegregates dominantly with abnormal proplatelet formation and macrothrombocytopenia. <i>Blood</i> , 2008, 111, 3407-3414.	0.6	94
121	P19INK4D links endomitotic arrest and megakaryocyte maturation and is regulated by AML-1. <i>Blood</i> , 2008, 111, 4081-4091.	0.6	47
122	JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. <i>Blood</i> , 2008, 112, 1402-1412.	0.6	159
123	Activating mutations in human acute megakaryoblastic leukemia. <i>Blood</i> , 2008, 112, 4220-4226.	0.6	141
124	The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity. <i>Blood</i> , 2008, 112, 2429-2438.	0.6	101
125	Megakaryocyte endomitosis is a failure of late cytokinesis related to defects in the contractile ring and Rho/Rock signaling. <i>Blood</i> , 2008, 112, 3164-3174.	0.6	171
126	Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis. <i>Blood</i> , 2007, 110, 3735-3743.	0.6	96

#	ARTICLE	IF	CITATIONS
127	Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. <i>Blood</i> , 2007, 109, 71-77.	0.6	154
128	Proplatelet formation is regulated by the Rho/ROCK pathway. <i>Blood</i> , 2007, 109, 4229-4236.	0.6	153
129	Interrelation between polyploidization and megakaryocyte differentiation: a gene profiling approach. <i>Blood</i> , 2007, 109, 3225-3234.	0.6	108
130	The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. <i>Blood</i> , 2007, 110, 1013-1021.	0.6	172
131	Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. <i>Blood</i> , 2007, 109, 2202-2204.	0.6	114
132	Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. <i>Blood</i> , 2006, 108, 346-352.	0.6	221
133	Reduced retention of radioprotective hematopoietic cells within the bone marrow microenvironment in CXCR4 ^Δ chimeric mice. <i>Blood</i> , 2006, 107, 2243-2251.	0.6	103
134	An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor. <i>Blood</i> , 2006, 107, 1864-1871.	0.6	137
135	Mammalian target of rapamycin (mTOR) regulates both proliferation of megakaryocyte progenitors and late stages of megakaryocyte differentiation. <i>Blood</i> , 2006, 107, 2303-2310.	0.6	84
136	The SCL relative LYL-1 is required for fetal and adult hematopoietic stem cell function and B-cell differentiation. <i>Blood</i> , 2006, 107, 4678-4686.	0.6	75
137	JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. <i>Blood</i> , 2006, 108, 1652-1660.	0.6	406
138	High molecular response rate of polycythemia vera patients treated with pegylated interferon \hat{A} -2a. <i>Blood</i> , 2006, 108, 2037-2040.	0.6	240
139	New Insights into the Pathogenesis of JAK2 V617F-Positive Myeloproliferative Disorders and Consequences for the Management of Patients. <i>Seminars in Thrombosis and Hemostasis</i> , 2006, 32, 341-351.	1.5	35
140	Deficiency in the Wiskott-Aldrich protein induces premature proplatelet formation and platelet production in the bone marrow compartment. <i>Blood</i> , 2006, 108, 134-140.	0.6	183
141	Monocyte/Macrophage Dysfunctions Do Not Impair the Promotion of Myelofibrosis by High Levels of Thrombopoietin. <i>Journal of Immunology</i> , 2006, 176, 6425-6433.	0.4	21
142	RGS16 is a negative regulator of SDF-1 \hat{A} CXCR4 signaling in megakaryocytes. <i>Blood</i> , 2005, 106, 2962-2968.	0.6	92
143	A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. <i>Nature</i> , 2005, 434, 1144-1148.	13.7	3,221
144	JAK1 and Tyk2 Activation by the Homologous Polycythemia Vera JAK2 V617F Mutation. <i>Journal of Biological Chemistry</i> , 2005, 280, 41893-41899.	1.6	151

#	ARTICLE	IF	CITATIONS
145	Mechanisms of WASp-mediated hematologic and immunologic disease. <i>Blood</i> , 2004, 104, 3454-3462.	0.6	134
146	Differential regulation of actin stress fiber assembly and proplatelet formation by $\alpha 2 \beta 1$ integrin and GPVI in human megakaryocytes. <i>Blood</i> , 2004, 104, 3117-3125.	0.6	98
147	FLI1 monoallelic expression combined with its hemizygous loss underlies Paris-Trousseau/Jacobsen thrombopenia. <i>Journal of Clinical Investigation</i> , 2004, 114, 77-84.	3.9	145
148	Megakaryocyte polyploidization is associated with a functional gene amplification. <i>Blood</i> , 2003, 101, 541-544.	0.6	75
149	Prominent role of TGF- $\beta 1$ in thrombopoietin-induced myelofibrosis in mice. <i>Blood</i> , 2002, 100, 3495-3503.	0.6	219
150	Distinct effects of thrombopoietin depending on a threshold level of activated Mpl in BaF-3 cells. <i>Journal of Cell Science</i> , 2002, 115, 2329-2337.	1.2	20
151	Asymmetrical segregation of chromosomes with a normal metaphase/anaphase checkpoint in polyploid megakaryocytes. <i>Blood</i> , 2001, 97, 2238-2247.	0.6	48
152	Role of p21Cip1/Waf1 in cell-cycle exit of endomitotic megakaryocytes. <i>Blood</i> , 2001, 98, 3274-3282.	0.6	65
153	Phenotypic and Functional Evidence for the Expression of CXCR4 Receptor During Megakaryocytopoiesis. <i>Blood</i> , 1999, 93, 1511-1523.	0.6	110
154	The Thrombocytopenia of Wiskott Aldrich Syndrome Is Not Related to a Defect in Proplatelet Formation. <i>Blood</i> , 1999, 94, 509-518.	0.6	85
155	Effects of Cytokines on Platelet Production From Blood and Marrow CD34+ Cells. <i>Blood</i> , 1998, 91, 830-843.	0.6	119
156	Endomitosis of Human Megakaryocytes Are Due to Abortive Mitosis. <i>Blood</i> , 1998, 91, 3711-3723.	0.6	161
157	High Thrombopoietin Production by Hematopoietic Cells Induces a Fatal Myeloproliferative Syndrome in Mice. <i>Blood</i> , 1997, 90, 4369-4383.	0.6	235